Validation of an automatic reference region extraction for the quantification of [18F]DPA-714 in dynamic brain PET studies.
There is a great need for a non-invasive methodology enabling the quantification of translocator protein overexpression in PET clinical imaging. [18F]DPA-714 has emerged as a promising translocator protein radiotracer as it is fluorinated, highly specific and returned reliable quantification using arterial input function. Cerebellum gray matter was proposed as reference region for simplified quantification; however, this method cannot be used when inflammation involves cerebellum. Here we adapted and validated a supervised clustering (supervised clustering algorithm (SCA)) for [18F]DPA-714 analysis. Fourteen healthy subjects genotyped for translocator protein underwent an [18F]DPA-714 PET, including 10 with metabolite-corrected arterial input function and three for a test-retest assessment. Two-tissue compartmental modelling provided [Formula: see text] estimates that were compared to either [Formula: see text] or [Formula: see text] generated by Logan analysis (using supervised clustering algorithm extracted reference region or cerebellum gray matter). The supervised clustering algorithm successfully extracted a pseudo-reference region with similar reliability using classes that were defined using either all subjects, or separated into HAB and MAB subjects. [Formula: see text], [Formula: see text] and [Formula: see text] were highly correlated (ICC of 0.91 ± 0.05) but [Formula: see text] were ∼26% higher and less variable than [Formula: see text]. Reproducibility was good with 5% variability in the test-retest study. The clustering technique for [18F]DPA-714 provides a simple, robust and reproducible technique that can be used for all neurological diseases.
1 Sorbonne Université, UPMC Paris 06, Institut du Cerveau et de la Moelle Epinière, ICM, Hôpital de la Pitié Salpêtrière, Paris, France.
Daniel
D
García-Lorenzo
2 Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de Recherche Fondamentale (DRF), Institut d'Imagerie Biomédicale (I2BM), MIRCen, Fontenay-aux-Roses, France.|3 Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay, Neurodegenerative Diseases Laboratory, Fontenay-aux-Roses, France.
Sonia
S
Lavisse
4 Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de Recherche Fondamentale (DRF), Institut d'Imagerie Biomédicale (I2BM), Service Hospitalier Frédéric Joliot, Orsay, France.|5 Imagerie Moléculaire in Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, Orsay, France.
Claire
C
Leroy
4 Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de Recherche Fondamentale (DRF), Institut d'Imagerie Biomédicale (I2BM), Service Hospitalier Frédéric Joliot, Orsay, France.|5 Imagerie Moléculaire in Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, Orsay, France.
Catriona
C
Wimberley
1 Sorbonne Université, UPMC Paris 06, Institut du Cerveau et de la Moelle Epinière, ICM, Hôpital de la Pitié Salpêtrière, Paris, France.
Benedetta
B
Bodini
2 Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de Recherche Fondamentale (DRF), Institut d'Imagerie Biomédicale (I2BM), MIRCen, Fontenay-aux-Roses, France.|3 Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay, Neurodegenerative Diseases Laboratory, Fontenay-aux-Roses, France.|7 Centre Expert Parkinson, Neurologie, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris and Université Paris-Est, Créteil, France.
Philippe
P
Remy
6 Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Mattia
M
Veronese
6 Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Federico
F
Turkheimer
1 Sorbonne Université, UPMC Paris 06, Institut du Cerveau et de la Moelle Epinière, ICM, Hôpital de la Pitié Salpêtrière, Paris, France.|8 Hôpital Saint Antoine, AP-HP, Paris, France.
Bruno
B
Stankoff
4 Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de Recherche Fondamentale (DRF), Institut d'Imagerie Biomédicale (I2BM), Service Hospitalier Frédéric Joliot, Orsay, France.|5 Imagerie Moléculaire in Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, Orsay, France.|9 Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département de Recherche Fondamentale (DRF), Institut d'Imagerie Biomédicale (I2BM),Neurospin, UNIACT, Gif-sur-Yvette, France.
Michel
M
Bottlaender
D000328:Adult; D000465:Algorithms; D001331:Automation; D001921:Brain / Q000000981:diagnostic imaging*; D002531:Cerebellum / Q000000981:diagnostic imaging; D016000:Cluster Analysis; D005260:Female; D005462:Fluorine Radioisotopes; D066128:Gray Matter / Q000000981:diagnostic imaging; D064368:Healthy Volunteers; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods / Q000592:standards*; D011720:Pyrazoles; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D018079:Receptors, GABA / Q000235:genetics; D015203:Reproducibility of Results
D005462:Fluorine Radioisotopes; C530129:N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide; D011720:Pyrazoles; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D018079:Receptors, GABA; C499229:TSPO protein, human
Inflammation; brain imaging and clinical trials; microglia; positron emission tomography